ALPINE IMMUNE SCIENCES INC's ticker is ALPN and the CUSIP is 02083G100. A total of 70 filers reported holding ALPINE IMMUNE SCIENCES INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $2,817,559 | +217.3% | 246,075 | +184.9% | 0.01% | +250.0% |
| Q2 2023 | $887,935 | +180.7% | 86,375 | +110.8% | 0.00% | +100.0% |
| Q1 2023 | $316,327 | -34.0% | 40,975 | -37.1% | 0.00% | 0.0% |
| Q4 2022 | $479,036 | -2.8% | 65,175 | -4.8% | 0.00% | 0.0% |
| Q3 2022 | $493,000 | -42.9% | 68,475 | -32.6% | 0.00% | -50.0% |
| Q2 2022 | $864,000 | -15.6% | 101,575 | -11.0% | 0.00% | -33.3% |
| Q1 2022 | $1,024,000 | -31.4% | 114,175 | +5.9% | 0.00% | -25.0% |
| Q4 2021 | $1,493,000 | +235.5% | 107,775 | +158.6% | 0.00% | +300.0% |
| Q3 2021 | $445,000 | -28.6% | 41,675 | -39.8% | 0.00% | -50.0% |
| Q2 2021 | $623,000 | -53.3% | 69,175 | -45.1% | 0.00% | -50.0% |
| Q1 2021 | $1,335,000 | +3.1% | 125,975 | +22.6% | 0.00% | +33.3% |
| Q4 2020 | $1,295,000 | +100.5% | 102,775 | +39.9% | 0.00% | +50.0% |
| Q3 2020 | $646,000 | – | 73,475 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 3,056,420 | $22,006,000 | 19.85% |
| Decheng Capital Management III (Cayman), LLC | 6,708,288 | $48,300,000 | 17.51% |
| GREAT POINT PARTNERS LLC | 3,448,521 | $24,829,000 | 5.98% |
| Omega Fund Management, LLC | 2,029,580 | $14,613,000 | 5.35% |
| Paradigm Biocapital Advisors LP | 2,214,722 | $15,946,000 | 2.13% |
| Frazier Life Sciences Management, L.P. | 2,985,757 | $21,497,000 | 1.66% |
| COMMODORE CAPITAL LP | 1,325,000 | $9,540,000 | 1.53% |
| Octagon Capital Advisors LP | 1,225,000 | $8,820,000 | 1.52% |
| RA Capital Management | 4,356,632 | $31,368,000 | 0.67% |
| TCG Crossover Management, LLC | 254,569 | $1,833,000 | 0.55% |